申请人:Qiu Yao-Ling
公开号:US20120039848A1
公开(公告)日:2012-02-16
The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
本发明揭示了公式(I)的化合物或其药学上可接受的盐、酯或前药,它们能够抑制RNA含量病毒,特别是丙型肝炎病毒(HCV)。因此,本发明的化合物干扰了丙型肝炎病毒的生命周期,并且也可用作抗病毒剂。本发明还涉及包含上述化合物的制药组合物,用于治疗患有HCV感染的受试者。本发明还涉及通过给受试者投予包含本发明化合物的制药组合物来治疗HCV感染的方法。